Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
Evidence-based prescribing requires taking into consideration the many aspects of optimal drug administration (e.g., dosage, comorbidities, co-administered drugs, etc.). A key issue is the administration of drugs for acute disorders that may potentially interfere with previously prescribed long-term...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Pharmacy |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2226-4787/11/4/130 |
| _version_ | 1797583484907159552 |
|---|---|
| author | Marios Spanakis Danny Alon-Ellenbogen Petros Ioannou Nikolaos Spernovasilis |
| author_facet | Marios Spanakis Danny Alon-Ellenbogen Petros Ioannou Nikolaos Spernovasilis |
| author_sort | Marios Spanakis |
| collection | DOAJ |
| description | Evidence-based prescribing requires taking into consideration the many aspects of optimal drug administration (e.g., dosage, comorbidities, co-administered drugs, etc.). A key issue is the administration of drugs for acute disorders that may potentially interfere with previously prescribed long-term medications. Initiating an antibiotic for an acute bacterial infection constitutes a common example. Hence, appropriate knowledge and awareness of the potential DDIs of antibiotics would lead to proper adjustments, thus preventing over- or under-treatment. For example, some statins, which are the most prescribed lipid-modifying agent (LMA), can lead to clinically important drug–drug interactions (DDIs) with the concurrent administration of antibiotics, e.g., macrolides. This review discusses the clinically significant DDIs of antibiotics associated with co-administrated lipid-lowering therapy and highlights common cases where regimen modifications may or may not be necessary. |
| first_indexed | 2024-03-10T23:38:36Z |
| format | Article |
| id | doaj.art-6acbc86009624c458ee0faa5f3da1442 |
| institution | Directory Open Access Journal |
| issn | 2226-4787 |
| language | English |
| last_indexed | 2024-03-10T23:38:36Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmacy |
| spelling | doaj.art-6acbc86009624c458ee0faa5f3da14422023-11-19T02:38:23ZengMDPI AGPharmacy2226-47872023-08-0111413010.3390/pharmacy11040130Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical ImplicationsMarios Spanakis0Danny Alon-Ellenbogen1Petros Ioannou2Nikolaos Spernovasilis3Department Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, 71003 Heraklion, GreeceDepartment of Basic and Clinical Sciences, University of Nicosia Medical School, 2417 Nicosia, CyprusDepartment of Internal Medicine & Infectious Diseases, University Hospital of Heraklion, 71110 Heraklion, GreeceDepartment of Infectious Diseases, German Oncology Center, 4108 Limassol, CyprusEvidence-based prescribing requires taking into consideration the many aspects of optimal drug administration (e.g., dosage, comorbidities, co-administered drugs, etc.). A key issue is the administration of drugs for acute disorders that may potentially interfere with previously prescribed long-term medications. Initiating an antibiotic for an acute bacterial infection constitutes a common example. Hence, appropriate knowledge and awareness of the potential DDIs of antibiotics would lead to proper adjustments, thus preventing over- or under-treatment. For example, some statins, which are the most prescribed lipid-modifying agent (LMA), can lead to clinically important drug–drug interactions (DDIs) with the concurrent administration of antibiotics, e.g., macrolides. This review discusses the clinically significant DDIs of antibiotics associated with co-administrated lipid-lowering therapy and highlights common cases where regimen modifications may or may not be necessary.https://www.mdpi.com/2226-4787/11/4/130antibioticslipid-modifying agentsdrug–drug interactionspharmaceutical careantibiotic stewardshipgood prescribing practices |
| spellingShingle | Marios Spanakis Danny Alon-Ellenbogen Petros Ioannou Nikolaos Spernovasilis Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications Pharmacy antibiotics lipid-modifying agents drug–drug interactions pharmaceutical care antibiotic stewardship good prescribing practices |
| title | Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications |
| title_full | Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications |
| title_fullStr | Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications |
| title_full_unstemmed | Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications |
| title_short | Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications |
| title_sort | antibiotics and lipid modifying agents potential drug drug interactions and their clinical implications |
| topic | antibiotics lipid-modifying agents drug–drug interactions pharmaceutical care antibiotic stewardship good prescribing practices |
| url | https://www.mdpi.com/2226-4787/11/4/130 |
| work_keys_str_mv | AT mariosspanakis antibioticsandlipidmodifyingagentspotentialdrugdruginteractionsandtheirclinicalimplications AT dannyalonellenbogen antibioticsandlipidmodifyingagentspotentialdrugdruginteractionsandtheirclinicalimplications AT petrosioannou antibioticsandlipidmodifyingagentspotentialdrugdruginteractionsandtheirclinicalimplications AT nikolaosspernovasilis antibioticsandlipidmodifyingagentspotentialdrugdruginteractionsandtheirclinicalimplications |